ArticleOrphanet journal of rare diseases2026
Care of patients with Phenylketonuria (PKU) in Germany - a claims data analysis from 2013 to 2023.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPhenylketonuria (PKU) is a rare inherited metabolic disorder requiring lifelong management to prevent neurological, psychiatric, and physical complications. Although early detection through newborn screening has improved outcomes, real-world evidence on long-term care and healthcare utilisation remains limited. This study assessed the epidemiology, comorbidities, treatment practices, rehabilitation and healthcare resource utilisation (HCRU) of individuals with PKU in Germany, using nationwide statutory health insurance (SHI) claims data over ten years.
resultsBased on anonymised claims data of 16 SHI funds (~ 4.4 million insured; 5% representative sample), 4,949-6,105 PKU patients were identified annually from 2013 to 2023, yielding a prevalence of 0.007%-0.008%. The five-year cumulative prevalence (2019-2023) was 0.010%, with a slight female predominance (52%). Compared to matched controls (1:10), PKU patients had higher odds of comorbidities, including intellectual disability (OR 16.0), other metabolic disorders (OR 9.2), osteoporosis (OR 3.4), hyperkinetic disorders (OR 2.1), and recurrent depressive disorders (OR 1.6), with the severity of cognitive impairment increasing with age. Less than 20% of the individuals received pharmacological treatment, with low incidences in patients older than 54 years. Nutritional therapy was common during childhood, adolescence and young adulthood (average 49% in ages 0-24) but declined with increasing age. Pregnancy terminations were documented in more than 15% of the 34 women with recorded pregnancy in the cohort. Rehabilitation care was overall higher than in the healthy population, especially among children aged 2-12 years (5.6% vs. 0.3% in controls), primarily for developmental disorders. Healthcare costs were considerably higher in the PKU cohort.
conclusionsPKU care in Germany exhibits age-dependent differences in documented treatment patterns and a high burden of comorbidities, highlighting a substantial unmet medical need and the importance of structured lifelong management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.